Novartis gets speedy review for CAR-T cell therapy
Novartis has stepped ahead in the race to get the first cancer-killing CAR-T cell therapy on the market having successfully filed a biologics license application with US regulators.
Read More
Tag: KTE-019
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
